US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Ongoing

Curosurf

Reason Lack of Assurance of Sterility

Chiesi USA, Inc. NDC 10122-510-03 D-0402-2026
Class II · Moderate risk Ongoing

Cinacalcet Hydrochloride Tablets

Reason CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc. D-0451-2026
Class II · Moderate risk Ongoing

Cinacalcet Hydrochloride Tablets

Reason CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc. D-0450-2026
Class II · Moderate risk Ongoing

Cinacalcet Hydrochloride Tablets

Reason CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit

Cipla USA, Inc. D-0449-2026
Class II · Moderate risk Ongoing

Meclizine Hydrochloride Tablets

Reason Failed tablet specifications.

Amerisource Health Services LLC NDC 60687-775-65 D-0418-2026
Class II · Moderate risk Ongoing

Buprenorphine Hydrochloride

Reason Crystallization; identified as Buprenorphine free base

ENDO USA, Inc. NDC 42023-179-05 D-0527-2026
Class II · Moderate risk Ongoing

Lanreotide Injection

Reason Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Cipla USA, Inc. NDC 69097-906-67 D-0423-2026
Class II · Moderate risk Ongoing

Lanreotide Injection

Reason Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Cipla USA, Inc. D-0422-2026
Class II · Moderate risk Ongoing

5% Dextrose Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0437-2026
Class II · Moderate risk Ongoing

5% Dextrose Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0436-2026
Class II · Moderate risk Ongoing

5% Dextrose Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0435-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0434-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0433-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0432-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0431-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0430-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0429-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0428-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0427-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0426-2026
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Kabi USA, LLC D-0425-2026
Class II · Moderate risk Ongoing

Icosapent Ethyl Capsules

Reason Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

Zydus Pharmaceuticals (USA) Inc D-0400-2026